MA57021B1 - Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients - Google Patents

Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Info

Publication number
MA57021B1
MA57021B1 MA57021A MA57021A MA57021B1 MA 57021 B1 MA57021 B1 MA 57021B1 MA 57021 A MA57021 A MA 57021A MA 57021 A MA57021 A MA 57021A MA 57021 B1 MA57021 B1 MA 57021B1
Authority
MA
Morocco
Prior art keywords
treatment
antibody
biomarker
level
therapy
Prior art date
Application number
MA57021A
Other languages
English (en)
French (fr)
Inventor
Jan Endell
Mark Winderlich
Rainer Boxhammer
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MA57021B1 publication Critical patent/MA57021B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA57021A 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients MA57021B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16171885 2016-05-30
PCT/EP2017/063045 WO2017207574A1 (en) 2016-05-30 2017-05-30 Methods for predicting therapeutic benefit of anti-cd19 therapy in patients

Publications (1)

Publication Number Publication Date
MA57021B1 true MA57021B1 (fr) 2024-05-31

Family

ID=56116221

Family Applications (2)

Application Number Title Priority Date Filing Date
MA57021A MA57021B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
MA45124A MA45124B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA45124A MA45124B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Country Status (27)

Country Link
US (2) US20190195879A1 (enExample)
EP (2) EP3916392B1 (enExample)
JP (2) JP7066639B2 (enExample)
KR (1) KR102416144B1 (enExample)
CN (2) CN115932265A (enExample)
AU (1) AU2017272608B2 (enExample)
BR (1) BR112018074603A2 (enExample)
CY (1) CY1124768T1 (enExample)
DK (2) DK3465214T3 (enExample)
EA (1) EA201892542A1 (enExample)
ES (2) ES2981046T3 (enExample)
FI (1) FI3916392T3 (enExample)
HR (2) HRP20240670T1 (enExample)
HU (2) HUE054860T2 (enExample)
IL (1) IL263103B2 (enExample)
LT (2) LT3465214T (enExample)
MA (2) MA57021B1 (enExample)
MD (2) MD3465214T2 (enExample)
MX (2) MX388502B (enExample)
PL (2) PL3465214T3 (enExample)
PT (2) PT3916392T (enExample)
RS (2) RS65540B1 (enExample)
SG (2) SG10201911958SA (enExample)
SI (2) SI3465214T1 (enExample)
SM (2) SMT202100291T1 (enExample)
WO (1) WO2017207574A1 (enExample)
ZA (2) ZA201808647B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115054697B (zh) 2015-08-21 2024-06-11 莫佛塞斯公司 抗-cd19抗体和磷酸肌醇3-激酶抑制剂的组合及其用途
PT3532098T (pt) 2016-10-28 2021-06-17 Morphosys Ag Combinação de anticorpo anti cd19 com um inibidor bcl-2 e suas utilizações
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
KR20220007087A (ko) * 2019-05-03 2022-01-18 모르포시스 아게 제한된 수의 nk 세포를 갖는 환자에서의 항-cd19 치료제
AU2020376305A1 (en) * 2019-10-31 2022-05-12 Incyte Corporation Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
TW202131950A (zh) * 2019-10-31 2021-09-01 德商莫菲西斯公司 依序抗ｃｄ１９療法
MX2023006538A (es) * 2020-12-04 2023-08-08 Morphosys Ag Terapia combinada de anticuerpo anti cúmulo de diferenciación 19 (cd19).

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004107B1 (ru) * 1998-08-11 2003-12-25 Айдек Фармацевтикалс Корпорэйшн Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
WO2002068414A2 (en) 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
DK1853718T3 (en) * 2005-02-15 2015-11-09 Univ Duke ANTI-CD19 ANTIBODIES AND THEIR USE IN ONCOLOGY
AU2006262232A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. CD19 antibodies and their uses
JP2009521912A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減された免疫原性を有する抗ｃｄ１９抗体
SI2059536T1 (sl) 2006-08-14 2014-06-30 Xencor, Inc. Optimirana protitelesa, ki ciljajo CD19
ATE551071T1 (de) 2006-09-08 2012-04-15 Medimmune Llc Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
WO2008032217A2 (fr) * 2006-09-13 2008-03-20 Glycode Methode d'investigation de la reponse a un traitement par un anticorps monoclonal
EP3392273A1 (en) 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
LT2211904T (lt) 2007-10-19 2016-11-25 Seattle Genetics, Inc. Cd19 surišantys agentai ir jų panaudojimas
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
CA2817842A1 (en) * 2010-11-15 2012-05-24 Medimmune, Llc Combination therapy for b cell lymphomas
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
PT2744826T (pt) * 2011-08-16 2022-05-19 Morphosys Ag Terapia de combinação com um anticorpo anti-cd19 e um análogo de purina
KR20200058583A (ko) * 2011-08-16 2020-05-27 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
US20140328842A1 (en) * 2011-12-12 2014-11-06 Pikamab, Inc. Predicting Responsiveness to Antibody Maintenance Therapy
EP3110445A4 (en) * 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CN106794231A (zh) 2014-06-16 2017-05-31 赞科股份有限公司 用于慢性淋巴细胞性白血病（cll）的治疗
JP6805137B2 (ja) * 2014-07-11 2020-12-23 アンセルム（アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 血液学的癌を診断するための方法

Also Published As

Publication number Publication date
HUE054860T2 (hu) 2021-10-28
SI3465214T1 (sl) 2021-12-31
AU2017272608B2 (en) 2023-08-10
PT3465214T (pt) 2021-06-30
MX2021014963A (es) 2022-02-24
RS65540B1 (sr) 2024-06-28
EP3465214A1 (en) 2019-04-10
HRP20210938T1 (hr) 2021-09-03
IL263103B1 (en) 2023-06-01
JP2022119764A (ja) 2022-08-17
HRP20240670T1 (hr) 2024-09-27
MX388502B (es) 2025-03-20
JP2019519770A (ja) 2019-07-11
SG10201911958SA (en) 2020-02-27
AU2017272608A1 (en) 2018-12-06
EP3916392B1 (en) 2024-05-01
KR20190013980A (ko) 2019-02-11
EP3465214B1 (en) 2021-04-28
US20220283166A1 (en) 2022-09-08
IL263103A (en) 2018-12-31
CN109313194A (zh) 2019-02-05
KR102416144B1 (ko) 2022-07-04
ZA201808647B (en) 2021-05-26
BR112018074603A2 (pt) 2019-03-19
LT3916392T (lt) 2024-08-26
CY1124768T1 (el) 2022-11-25
EP3916392A1 (en) 2021-12-01
SMT202400204T1 (it) 2024-09-16
JP7066639B2 (ja) 2022-05-13
ES2878156T3 (es) 2021-11-18
PT3916392T (pt) 2024-06-04
NZ748468A (en) 2025-05-30
MX2018014702A (es) 2019-10-02
HUE067450T2 (hu) 2024-10-28
CN115932265A (zh) 2023-04-07
IL263103B2 (en) 2023-10-01
FI3916392T3 (fi) 2024-06-03
CA3025823A1 (en) 2017-12-07
SMT202100291T1 (it) 2021-07-12
MD3465214T2 (ro) 2021-09-30
PL3916392T3 (pl) 2024-09-23
SI3916392T1 (sl) 2024-10-30
RS62155B1 (sr) 2021-08-31
DK3916392T3 (da) 2024-05-21
LT3465214T (lt) 2021-10-11
MA45124B1 (fr) 2021-05-31
JP7511806B2 (ja) 2024-07-08
DK3465214T3 (da) 2021-05-31
WO2017207574A1 (en) 2017-12-07
ES2981046T3 (es) 2024-10-07
ZA202100296B (en) 2025-05-28
CN109313194B (zh) 2022-11-04
EA201892542A1 (ru) 2019-06-28
MA45124A (fr) 2017-12-07
US20190195879A1 (en) 2019-06-27
SG11201810159TA (en) 2018-12-28
PL3465214T3 (pl) 2021-12-20
MD3916392T2 (ro) 2024-10-31

Similar Documents

Publication Publication Date Title
MA57021B1 (fr) Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
Lampson et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Varettoni et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms
Mercer et al. Expression and function of TNF and IL-1 receptors on human regulatory T cells
Fan et al. Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation
Coffey et al. Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed/refractory B-cell malignancies
Galatola et al. Gene expression profile of peripheral blood monocytes: a step towards the molecular diagnosis of celiac disease?
Dengler et al. Cellular changes in blood indicate severe respiratory disease during influenza infections in mice
Akhter et al. CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series
Sippert et al. Association of duffy blood group gene polymorphisms with IL8 gene in chronic periodontitis
Worasilchai et al. Monitoring anti-Pythium insidiosum IgG antibodies and (1→ 3)-β-d-Glucan in vascular pythiosis
Kim et al. Pathogenic genotype of major piroplasm surface protein associated with anemia in Theileria orientalis infection in cattle
Angelot‐Delettre et al. Intracytoplasmic detection of TCL1—but not ILT7—by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis
US10725029B2 (en) Kit for in vitro or ex vivo measurement of SCD127 expression in a biological sample
Isidro-Hernández et al. Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice
Ilhan et al. Leukemic stem cells shall be searched in the bone marrow before “tyrosine kinase inhibitor‐discontinuation” in chronic myeloid leukemia
Sun et al. Glioblastoma cellular MAP4K1 facilitates tumor growth and disrupts T effector cell infiltration
Flinterman et al. Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk
Yamauchi et al. Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma
Hartling et al. Gene variation in IL-7 receptor (IL-7R) α affects IL-7R response in CD4+ T cells in HIV-infected individuals
Vairaktaris et al. A DNA polymorphism of stromal-derived factor-1 is associated with advanced stages of oral cancer
Walker et al. The effect of systemic corticosteroid therapy on the expression of toll‐like receptor 2 and toll‐like receptor 4 in the cutaneous lesions of leprosy Type 1 reactions
Gossmann et al. A gain-of-function mutation in the Plcg2 gene protects mice from helicobacter felis-induced gastric MALT lymphoma
US20190086415A1 (en) Treating patients based on immune subtypes
Gibson et al. Inherited genetic variation and overall survival following follicular lymphoma